VENUS MEDTECH-B

Hangzhou Qiming Medical Devices Co., Ltd. (“Qiming Medical”) is the leading enterprise in the field of minimally invasive interventional treatment of heart valves in China, and is committed to the development and commercialization of innovative medical devices in the field of structural heart disease. Qiming Medical was founded in 2009 and is located in Hangzhou National High-tech Industrial Development Zone (Binjiang). In 2014, the company won the national biomedical industry championship with the “Novel Biological Heart Aortic Valve Project” and stood out in this field. The company has four “No. 1 in China” titles: the first to begin and complete NMPA registered clinical research in China, the first is a cardiovascular device supported by the NMPA innovation channel, the first is a Chinese heart valve device that enters Europe for clinical implantation in humans, and the first is an enterprise approved to establish a heart valve research institute in China. On December 10, 2019, the company was successfully listed on the main board of the Hong Kong Stock Exchange with the stock code 02500. At present, Qiming Medical has established a comprehensive solution for structural heart disease, covering a complete pipeline of heart valve diseases such as aortic, pulmonary, mitral, and tricuspid valves, hypertrophic cardiomyopathy, hypertensive renal artery desympathetic ablation, and surgical ancillary products. By the end of August 2021, Qiming Medical had a total of 507 patents and patent applications, including 209 authorized invention patents. The main countries and regions of the layout include China, the United States, Europe, Japan, Canada, Russia, India, Brazil, etc. As a local innovative enterprise, Qiming Medical has received many awards and honors, including the 12th and 13th National Science and Technology Support Plan awards assessed by the Ministry of Science and Technology of China, the country's second batch of specialized, special and new “little giant” enterprises, China's Outstanding Patent Award, outstanding domestic medical equipment products, and national high-tech enterprises. In the future, Qiming Medical will focus on developing new materials, bionics, influence fusion technology and digital sensing directions, continuously update and iterate, and promote innovation to meet the needs of a wide range of doctors and patients. The company will not only act as a leader in the field of heart valves, but also expect the Qiming medical model to provide a strong reference for the development of China's innovative medical industry. Innovation leads the future, and Qiming Medical will continue to work on the development and marketization of innovative medical equipment for structural heart disease to accelerate innovation in China and benefit the world.